Your browser doesn't support javascript.
loading
Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension.
Westgate, Connar Sj; Botfield, Hannah F; Alimajstorovic, Zerin; Yiangou, Andreas; Walsh, Mark; Smith, Gabrielle; Singhal, Rishi; Mitchell, James L; Grech, Olivia; Markey, Keira A; Hebenstreit, Daniel; Tennant, Daniel A; Tomlinson, Jeremy W; Mollan, Susan P; Ludwig, Christian; Akerman, Ildem; Lavery, Gareth G; Sinclair, Alexandra J.
Afiliação
  • Westgate CS; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Botfield HF; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
  • Alimajstorovic Z; Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Yiangou A; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Walsh M; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
  • Smith G; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Singhal R; Department of Neurology, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Mitchell JL; School of Life Sciences, University of Warwick, Coventry, United Kingdom.
  • Grech O; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Markey KA; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
  • Hebenstreit D; Upper GI Unit and Minimally Invasive Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham United Kingdom.
  • Tennant DA; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Tomlinson JW; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
  • Mollan SP; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Ludwig C; Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
  • Akerman I; Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Lavery GG; Department of Neurology, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Sinclair AJ; School of Life Sciences, University of Warwick, Coventry, United Kingdom.
JCI Insight ; 6(10)2021 05 24.
Article em En | MEDLINE | ID: mdl-33848268
BACKGROUNDIdiopathic intracranial hypertension (IIH) is a condition predominantly affecting obese women of reproductive age. Recent evidence suggests that IIH is a disease of metabolic dysregulation, androgen excess, and an increased risk of cardiovascular morbidity. Here we evaluate systemic and adipose specific metabolic determinants of the IIH phenotype.METHODSIn fasted, matched IIH (n = 97) and control (n = 43) patients, we assessed glucose and insulin homeostasis and leptin levels. Body composition was assessed along with an interrogation of adipose tissue function via nuclear magnetic resonance metabolomics and RNA sequencing in paired omental and subcutaneous biopsies in a case-control study.RESULTSWe demonstrate an insulin- and leptin-resistant phenotype in IIH in excess of that driven by obesity. Adiposity in IIH is preferentially centripetal and is associated with increased disease activity and insulin resistance. IIH adipocytes appear transcriptionally and metabolically primed toward depot-specific lipogenesis.CONCLUSIONThese data show that IIH is a metabolic disorder in which adipose tissue dysfunction is a feature of the disease. Managing IIH as a metabolic disease could reduce disease morbidity and improve cardiovascular outcomes.FUNDINGThis study was supported by the UK NIHR (NIHR-CS-011-028), the UK Medical Research Council (MR/K015184/1), Diabetes UK, Wellcome Trust (104612/Z/14/Z), the Sir Jules Thorn Award, and the Midlands Neuroscience Teaching and Research Fund.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Pseudotumor Cerebral / Adipócitos / Leptina / Insulina / Obesidade Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: JCI Insight Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Pseudotumor Cerebral / Adipócitos / Leptina / Insulina / Obesidade Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: JCI Insight Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido